Hans Christoph DienerTeiji AkagiKritvikrom DurongpisitkulViji Samuel ThomsonA. T. PrabhakarRoss SharpeBert AlbersThorsten LewalterKoichi OkiVijay K. SharmaNational University Hospital, SingaporeYong Loo Lin School of MedicineOkayama UniversityUniversität Duisburg-EssenFaculty of Medicine, Siriraj Hospital, Mahidol UniversitySaiseikai Central HospitalChristian Medical College, VelloreAlbers Clinical Evidence ConsultancyPeter Osypka Heart CenterCardiology Department2020-08-252020-08-252020-01-01International Journal of Stroke. (2020)17474949174749302-s2.0-85088090011https://repository.li.mahidol.ac.th/handle/20.500.14594/58351© 2020 World Stroke Organization. Recently published long-term data from randomized controlled trials have provided evidence for the prevention of recurrent embolic stroke of undetermined source by percutaneous closure of the patent foramen ovale. However, most data were obtained from Caucasian populations and evidence on patent foramen ovale closure in Asian-Pacific patients is limited. The relative paucity in clinical data from this population, as well as the fact that Asian-Pacific patients may have higher bleeding risks than Caucasians, complicates clinical decision-making. This document, resulting from a consensus meeting of Asian-Pacific clinical experts, states the consensus among these experts about how to treat Asian-Pacific patients who had an embolic stroke of undetermined source and have a patent foramen ovale, based on currently available evidence and expert opinions. In addition, uncertainties and the need for clinical data regarding patent foramen ovale closure for prevention of recurrent embolic stroke of undetermined source in general, and specifically for Asian-Pacific patients, are identified.Mahidol UniversityNeuroscienceArticleSCOPUS10.1177/1747493020941658